CABG trial, virus knockdowns in cultures

Posted by:

Jon Moulton (group admin)

Date:

26 October 2007

Comments:

0 comments

A clinical trial to prevent reblocking of coronary artery bypass grafts is ongoing in Poland. This trial uses a Morpholino conjugated with a cell-penetrating peptide. Successful protein knockdown should halt the cell cycle.

http://clinicaltrials.gov/ct/show/NCT00451256?order=1

Here are a few recent papers describing knockdowns of viral replication in cell cultures using peptide-conjugated Morpholinos.

Patel D, Opriessnig T, Stein DA, Halbur PG, Meng XJ, Iversen PL, Zhang YJ. Peptide-conjugated morpholino oligomers inhibit porcine reproductive and respiratory syndrome virus replication. Antiviral Res. 2007 Oct 4; [Epub ahead of print]

Vagnozzi A, Stein DA, Iversen PL, Rieder E. Inhibition of foot-and-mouth disease virus in cell cultures with antisense Morpholino oligomers. J Virol. 2007 Aug 29; [Epub ahead of print]

Please note only group admins can post notices. Group members can post comments.